XML 66 R59.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Intangible Assets (Narrative) (Details) (USD $) | 12 Months Ended | 0 Months Ended |
--- | --- | --- | ---
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 29, 2013 | Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Amortization of intangible assets | $ 1,596,689 us-gaap_AmortizationOfIntangibleAssets | $ 896,156 us-gaap_AmortizationOfIntangibleAssets | $ 506,332 us-gaap_AmortizationOfIntangibleAssets |  |
Additions to intangible assets | 3,101,565 us-gaap_PaymentsToAcquireIntangibleAssets | 7,462,080 us-gaap_PaymentsToAcquireIntangibleAssets | 2,071,926 us-gaap_PaymentsToAcquireIntangibleAssets |  |
Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, gross | 16,477,749 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = cpix_ProductAndLicenseRightsMember | 12,139,031 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = cpix_ProductAndLicenseRightsMember |  |  |
Patents |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, gross | 8,194,264 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember | 4,866,570 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember |  |  |
Additions to intangible assets | 3,300,000 us-gaap_PaymentsToAcquireIntangibleAssets / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember | 2,100,000 us-gaap_PaymentsToAcquireIntangibleAssets / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_PatentsMember |  |  |
Product, Kristalose | Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, useful life | 15 years |  |  |  |
Collaborative Arrangement, Amended International Agreement |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Other revenue, potential upfront payment related to product sales |  | 4,000,000 cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales / us-gaap_TypeOfArrangementAxis = cpix_AmendedInternationalAgreementMember |  |  |
Product Rights Agreement, U.S. Commercialization Rights for Kristalose from Inalco Biochemicals, Inc. and Inalco S.p.A. | Product, Kristalose | Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Product rights agreement, quarterly payments, expiration date | 7 years |  |  |  |
Quarterly payments made | 1,300,000 cpix_ProductRightsAgreementQuarterlyPaymentsMade / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = cpix_ProductAndLicenseRightsMember / us-gaap_ProductOrServiceAxis = cpix_KristaloseMember / us-gaap_TypeOfArrangementAxis = cpix_ProductRightsAgreementUSCommercializationRightsForKristaloseFromInalcoBiochemicalsIncAndInalcoSPAMember | 800,000 cpix_ProductRightsAgreementQuarterlyPaymentsMade / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = cpix_ProductAndLicenseRightsMember / us-gaap_ProductOrServiceAxis = cpix_KristaloseMember / us-gaap_TypeOfArrangementAxis = cpix_ProductRightsAgreementUSCommercializationRightsForKristaloseFromInalcoBiochemicalsIncAndInalcoSPAMember |  |  |
Product, Vaprisol | Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, gross |  |  |  |  | 3,000,000 us-gaap_FiniteLivedIntangibleAssetsGross / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = cpix_ProductAndLicenseRightsMember / dei_LegalEntityAxis = cpix_VaprisolMember
Pernix Therapeutics | Collaborative Arrangement, Amended International Agreement |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Other revenue, potential upfront payment related to product sales | $ 3,000,000 cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales / dei_LegalEntityAxis = cpix_PernixTherapeuticsMember / us-gaap_TypeOfArrangementAxis = cpix_AmendedInternationalAgreementMember |  |  | $ 4,000,000 cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales / dei_LegalEntityAxis = cpix_PernixTherapeuticsMember / us-gaap_TypeOfArrangementAxis = cpix_AmendedInternationalAgreementMember |

X
- Definition Product rights agreement, quarterly payments, expiration date + References No definition available. + Details
Name: | cpix_ProductRightsAgreementQuarterlyPaymentsExpirationDate
Namespace Prefix: | cpix_
Data Type: | us-types:durationStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product Rights Agreement, Quarterly Payments Made + References No definition available. + Details
Name: | cpix_ProductRightsAgreementQuarterlyPaymentsMade
Namespace Prefix: | cpix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue Recognition, Potential Upfront Payment Related to Product Sales + References No definition available. + Details
Name: | cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
Namespace Prefix: | cpix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=cpix_PernixTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cpix_VaprisolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=cpix_KristaloseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cpix_ProductRightsAgreementUSCommercializationRightsForKristaloseFromInalcoBiochemicalsIncAndInalcoSPAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |